Preparation method of platelet-derived hemostatic as well as product and application of platelet-derived hemostatic

By preparing the platelet-derived hemostatic agent hPPL, the problem of low hemostatic efficiency and poor biocompatibility of existing hemostatic materials in visceral bleeding and wet tissue surfaces is solved by utilizing the procoagulant mechanism of platelets, thus achieving a highly efficient and safe hemostatic effect.

CN118924789APending Publication Date: 2024-11-12THE NAT CENT FOR NANOSCI & TECH NCNST OF CHINA +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410983473.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-22
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Existing hemostatic materials are inadequate in terms of hemostatic efficiency and biocompatibility, especially in visceral bleeding and hemostasis of wet tissue surfaces, and may cause inflammatory reactions or thrombosis, making it difficult to meet clinical needs.

Method used

The platelet-derived hemostatic agent hPPL was prepared by mixing whole blood with an anticoagulant, centrifuging, resuspending, and treating with calcium ion carrier A23187. The platelet derivative hPPL with procoagulant function was prepared by utilizing the natural procoagulant mechanism of platelets to promote thrombin generation and fibrin formation.

Benefits of technology

hPPL exhibits highly efficient hemostatic properties, significantly shortens clotting time, reduces the risk of distal thrombosis, and has good biocompatibility. It is suitable for patients with visceral bleeding and coagulation disorders and has broad clinical application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924789A_ABST
    Figure CN118924789A_ABST
Patent Text Reader

Abstract

The invention relates to a preparation method of a platelet-derived hemostatic as well as a product and application of the platelet-derived hemostatic, the preparation method comprises the following steps: mixing whole blood and an anticoagulant, and centrifuging to obtain platelet-rich plasma; centrifuging the platelet-rich plasma to obtain platelet precipitate; re-suspending the platelet precipitate by using a platelet re-suspension, and centrifuging to obtain platelets; and mixing the blood platelets with the buffer solution containing the calcium ion carrier, standing, and centrifuging to obtain the blood platelets. The preparation process is simple and controllable, the toxic effect and degradation problems of materials such as compounds are eliminated, the product coagulation accelerating efficiency is high, and compared with existing hemostatic materials, the platelet-derived hemostatic has good biocompatibility, does not need to be absorbed and degraded, has a unique coagulation accelerating mechanism, and is more remarkable in hemostatic effect and wider in application range.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine and relates to a preparation method of a platelet-derived hemostatic agent and its product and application. Background Art

[0002] Uncontrolled massive bleeding is an important cause of human death under conditions such as disease, surgery, and battlefields. In particular, hemostasis treatment of incompressible visceral bleeding, including liver bleeding, heart bleeding, and gastrointestinal bleeding, is an unresolved clinical challenge. The resulting uncontrolled bleeding will seriously threaten the patient's life. In a special military environment, bleeding from severe wounds is an important factor leading to the death of soldiers. A retrospective survey of the causes of death of soldiers in the Israeli military environment showed that the number of deaths caused by bleeding on the battlefield can reach 50% of the total number of deaths. Especially for soldiers who suffer penetrating injuries, only timely and effective hemostasis can continue to receive treatment and increase the chance of survival.

[0003] The types of hemostatic materials currently available include gauze, hemostatic powder, hydrogel and hemostatic sponge, etc., and their hemostatic mechanisms include three categories: one is to physically seal the bleeding wound directly through physical adhesion to achieve hemostasis, such as strong biological adhesives. However, this type of hemostatic agent has weak adhesion to the wet tissue surface, low hemostatic efficiency, and is mostly composed of biologically toxic compound molecules, such as amino acrylates, which are prone to cause cytotoxicity and immune reactions, so it is difficult to use for hemostatic treatment of visceral bleeding. Another type relies on absorbing excess fluid in the blood to locally concentrate coagulation factors to promote coagulation, but it also has the disadvantages of low hemostatic efficiency and easy to cause inflammatory reactions. At the same time, this type of hemostatic agent may also cause problems such as wound adhesion and secondary bleeding. The third type mainly promotes coagulation by adding procoagulant factors to the material, but this type of hemostatic agent has the risk of being released into the vascular system, leading to distal vascular thrombosis. Therefore, it is of great clinical and social significance to develop new hemostatic materials with good biocompatibility, high hemostatic efficiency, and easy preparation and storage to solve the problems of existing hemostatic agents and achieve safe and efficient treatment of related diseases such as tissue and organ bleeding.

[0004] Platelets (PLT) are the "first responders" to bleeding and play a key role in the physiological hemostasis process. When bleeding occurs, platelets can recognize and specifically adhere to the bleeding injury site, and form platelet plugs through activation and aggregation. After that, the activated platelets further promote thrombin generation and fibrin formation to amplify the coagulation reaction cascade, and finally form a stable blood clot at the bleeding site to complete hemostasis. In the platelet-mediated coagulation process, phosphatidylserine (PS) exposed on the surface of activated platelets can promote the conversion of prothrombin to thrombin, thereby promoting the cascade amplification of the coagulation reaction. After platelets adhere to damaged blood vessels, they are rapidly activated, causing the PS located in the inner leaflet of the platelet membrane to flip to the outer leaflet, thereby forming a platelet procoagulant surface, providing binding sites for prothrombin, factor Xa, factor Va, etc., promoting the formation of prothrombin complexes, and allowing thrombin to be generated in large quantities at the bleeding site. Thrombin then catalyzes the conversion of fibrinogen into fibrin, forming a clot at the damaged blood vessel to block bleeding. Whether it is possible to utilize the natural procoagulant function of platelets and directly transform platelets into efficient and safe hemostatic agents through simple and controllable preparation methods has not yet been reported. Summary of the invention

[0005] In view of the deficiencies of the prior art, the object of the present invention is to provide a method for preparing a platelet-derived hemostatic agent and its product and application.

[0006] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:

[0007] In a first aspect, the present invention provides a method for preparing a platelet-derived hemostatic agent, the preparation method comprising:

[0008] (1) Mixing whole blood with an anticoagulant and centrifuging to obtain platelet-rich plasma;

[0009] (2) centrifuging the platelet-rich plasma to obtain a platelet precipitate;

[0010] (3) resuspending the platelet pellet using a platelet resuspension solution;

[0011] (4) The platelets are mixed with a buffer solution containing a calcium ion carrier, allowed to stand, and then centrifuged to obtain the product.

[0012] In order to invent a hemostatic agent with good biosafety, high hemostatic efficiency, and can be used for hemostatic treatment of tissue and visceral bleeding, we designed and developed a platelet-derived high-efficiency hemostatic agent based on the role of platelets in the physiological hemostatic process, and named it hPPL, which is used for hemostatic treatment of incompressible visceral bleeding such as liver bleeding and gastrointestinal bleeding. After a series of condition optimizations, we successfully prepared the procoagulant platelet derivative hPPL by stimulating platelets with the calcium ion carrier A23187. hPPL has a surface morphology, particle size, and protein composition similar to those of resting platelets, and also shows a strong procoagulant ability. hPPL can induce normal platelet activation, enhance platelet aggregation, and promote the production of thrombin and fibrin to achieve rapid coagulation. Mechanistically, our results prove that the procoagulant function of hPPL is related to surface PS exposure and upregulation of prostaglandin E synthase (PTGES). Excessive PS exposed on the surface of hPPL accelerates coagulation by promoting thrombin generation. In addition, we screened proteomics data and found that the level of PTGES on the hPPL membrane surface was upregulated. PTGES increased the production of PGE2 (prostaglandin E2) in plasma. Subsequently, PGE2 bound to the EP3 receptor on the platelet surface, causing platelet activation and promoting coagulation. Our results also demonstrated that hPPL showed better hemostatic effects than commercially available hemostatic materials in rat liver bleeding models and pig gastric ulcer bleeding models. In short, hPPL has a simple preparation process, strong procoagulant ability, good biosafety, and broad prospects for clinical application.

[0013] Preferably, the whole blood comprises mouse whole blood, porcine whole blood or human whole blood.

[0014] Preferably, the volume ratio of whole blood to anticoagulant is (5-7):1, wherein the specific point values ​​in (5-7) can be selected from 5, 5.2, 5.4, 5.6, 5.8, 6, 6.2, 6.4, 6.6, 6.8, 7, etc. Other specific point values ​​within the above numerical range can be selected, and they will not be described one by one here.

[0015] Preferably, the anticoagulant comprises prostaglandin E12-10 μM, citric acid 35-45 mM, sodium citrate 75-90 mM, d-glucose 120-140 mM and water.

[0016] The concentration of the prostaglandin E1 can be selected from 2μM, 3μM, 4μM, 5μM, 6μM, 7μM, 8μM, 9μM, 10μM, etc., the concentration of citric acid can be selected from 35mM, 36mM, 37mM, 38mM, 39mM, 40mM, 41mM, 42mM, 43mM, 44mM, 45mM, etc., and the concentration of sodium citrate can be selected from 75mM, 76mM, 77mM, 78mM, 79mM, 80mM , 81mM, 82mM, 83mM, 84mM, 85mM, 86mM, 87mM, 88mM, 89mM, 90mM, etc. The concentration of d-glucose can be selected as 120mM, 122mM, 124mM, 126mM, 128mM, 130mM, 132mM, 134mM, 136mM, 138mM, 140mM, etc. Other specific point values ​​within the above numerical range can be selected, so they will not be described here one by one.

[0017] Preferably, the pH of the anticoagulant is 7-7.4, such as 7, 7.1, 7.2, 7.3, 7.4, etc. Other specific values ​​within the above numerical range can be selected and will not be described one by one here.

[0018] Preferably, the centrifugation speed in step (1) is 100-180g and the time is 20-40min.

[0019] The rotation speed can be selected as 100g, 110g, 120g, 130g, 140g, 150g, 160g, 170g, 180g, etc., and the time can be selected as 20min, 22min, 24min, 26min, 28min, 30min, 32min, 34min, 36min, 38min, 40min, etc. Other specific point values ​​within the above numerical range can be selected, so they will not be elaborated here.

[0020] Preferably, the centrifugal speed in step (2) and step (3) is independently 1000-2000 g, and the time is independently 5-15 min.

[0021] The rotation speed can be selected as 1000g, 1100g, 1200g, 1300g, 1400g, 1500g, 1600g, 1700g, 1800g, 1900g, 2000g, etc., and the time can be selected as 5min, 6min, 7min, 8min, 9min, 10min, 11min, 12min, 13min, 14min, 15min, etc. Other specific point values ​​within the above numerical range can be selected, so they will not be elaborated here.

[0022] Preferably, the platelet resuspension solution comprises prostaglandin E12-10 μM, citric acid 7-8 mM, sodium citrate 15-18 mM, d-glucose 24-28 mM, NaCl 96-112 mM, KCl 2-2.8 mM, MgCl 2 0.5-1.2 mM, NaHCO 3 8-12mM, Na 2 HPO 4 0.24-0.32 mM, HEPES 4-12 mM, phenylmethylsulfonyl fluoride 6-10 mM and water.

[0023] The water is ultrapure water.

[0024] The concentration of the prostaglandin E1 can be selected from 2μM, 3μM, 4μM, 5μM, 6μM, 7μM, 8μM, 9μM, 10μM, etc., the concentration of citric acid can be selected from 7mM, 7.1mM, 7.2mM, 7.3mM, 7.4mM, 7.5mM, 7.6mM, 7.7mM, 7.8mM, 7.9mM, 8mM, etc., and the concentration of sodium citrate can be You can choose 15mM, 15.2mM, 15.4mM, 15.6mM, 15.8mM, 16mM, 16.2mM, 16.4mM, 16.6mM, 16.8mM, 17mM, 17.2mM, 17.4mM, 17.6mM, 17.8mM, 18mM, etc. The concentration of d-glucose can be 24mM, 24.2mM, 24.5 mM, 24.8mM, 25mM, 25.2mM, 25.5mM, 25.8mM, 26mM, 26.2mM, 26.5mM, 26.8mM, 27mM, 27.2mM, 27.5mM, 27.8mM, 28mM, etc. The concentration of NaCl can be 96mM, 97mM, 98mM, 99mM, 100mM, 101m The concentration of KCl can be selected as 2mM, 2.1mM, 2.2mM, 2.3mM, 2.4mM, 2.5mM, 2.6mM, 2.7mM, 2.8mM, etc. The concentration of MgCl 2 The concentration of NaHCO can be selected from 0.5mM, 0.6mM, 0.7mM, 0.8mM, 0.9mM, 1mM, 1.1mM, 1.2mM, etc. 3 The concentration can be selected from 8mM, 9mM, 10mM, 11mM, 12mM, etc. 2 HPO 4The concentration of can be selected as 0.24mM, 0.25mM, 0.26mM, 0.27mM, 0.28mM, 0.29mM, 0.3mM, 0.31mM, 0.32mM, etc., the concentration of HEPES can be selected as 4mM, 5mM, 6mM, 7mM, 8mM, 9mM, 10mM, 11mM, 12mM, etc., the concentration of phenylmethylsulfonyl fluoride can be selected as 6mM, 7mM, 8mM, 9mM, 10mM, etc., and other specific point values ​​within the above numerical range can be selected, so they will not be described one by one here.

[0025] The addition of phenylmethylsulfonyl fluoride and prostaglandin E1 is very important. Failure to add them or too low a concentration will cause platelet aggregation and subsequent experiments will not be possible.

[0026] Preferably, the pH of the platelet resuspension is 7-7.4, such as 7, 7.1, 7.2, 7.3, 7.4, etc. Other specific values ​​within the above numerical range can be selected and will not be described here one by one.

[0027] The buffer containing calcium ionophore includes calcium ionophore 15-30μM, CaCl 2 1-2 mM, NaCl 120-140mM, KCl 2.5-3.5mM, MgCl 2 0.5-1.5 mM, NaHCO 3 10-15 mM, Na 2 HPO 4 0.3-0.4 mM, HEPES 5-15 mM and water.

[0028] The concentration of the calcium ion carrier can be selected from 15 μM, 16 μM, 17 μM, 18 μM, 19 μM, 20 μM, 21 μM, 22 μM, 23 μM, 24 μM, 25 μM, 26 μM, 27 μM, 28 μM, 29 μM, 30 μM, etc., CaCl 2 The concentration of can be selected from 1mM, 1.1mM, 1.2mM, 1.3mM, 1.4mM, 1.5mM, 1.6mM, 1.7mM, 1.8mM, 1.9mM, 2mM, etc., the concentration of NaCl can be selected from 120mM, 122mM, 124mM, 126mM, 128mM, 130mM, 132mM, 134mM, 136mM, 138mM, 140mM, etc., the concentration of KCl can be selected from 2.5mM, 2.6mM, 2.7mM, 2.8mM, 2.9mM, 3mM, 3.1mM, 3.2mM, 3.3mM, 3.4mM, 3.5mM, etc., the concentration of MgCl 2The concentration of NaHCO can be selected from 0.5mM, 0.6mM, 0.7mM, 0.8mM, 0.9mM, 1mM, 1.1mM, 1.2mM, 1.3mM, 1.4mM, 1.5mM, etc. 3 The concentration can be selected from 10mM, 11mM, 12mM, 13mM, 14mM, 15mM, etc. 2 HPO 4 The concentration of can be selected as 0.3mM, 0.31mM, 0.32mM, 0.33mM, 0.34mM, 0.35mM, 0.36mM, 0.37mM, 0.38mM, 0.39mM, 0.4mM, etc., the concentration of HEPES can be selected as 5mM, 6mM, 7mM, 8mM, 9mM, 10mM, 11mM, 12mM, 13mM, 14mM, 15mM, etc., the concentration of phenylmethylsulfonyl fluoride can be selected as 8mM, 8.5mM, 9mM, 9.5mM, 10mM, 10.5mM, 11mM, 11.5mM, 12mM, etc., and other specific point values ​​within the above numerical range can be selected, so they will not be described one by one here.

[0029] Preferably, the pH of the buffer solution containing calcium ion carrier is 7-7.4, such as 7, 7.1, 7.2, 7.3, 7.4, etc. Other specific values ​​within the above numerical range can be selected and will not be described one by one here.

[0030] Preferably, the calcium ion carrier comprises A23187.

[0031] Preferably, the standing temperature in step (4) is 20-25° C. and the standing time is 3-8 min.

[0032] The temperature can be selected as 20°C, 21°C, 22°C, 23°C, 24°C, 25°C, etc., and the time can be selected as 3min, 3.5min, 4min, 4.5min, 5min, 5.5min, 6min, 6.5min, 7min, 7.5min, 8min, etc. Other specific point values ​​within the above numerical range can be selected, and they will not be elaborated here.

[0033] Preferably, the centrifugation in step (4) further includes washing 1-3 times, for example, once, twice, three times, etc. Other specific point values ​​within the above numerical range can be selected and will not be described in detail here.

[0034] The washing method comprises: resuspending the product obtained by centrifugation with a washing solution, and centrifuging at 4500-6000g (e.g., 4500g, 4600g, 4700g, 4800g, 4900g, 5000g, 5100g, 5200g, 5300g, 5400g, 5500g, 5600g, 5700g, 5800g, 5900g, 6000g, etc.) for 5-10min (e.g., 5min, 5.5min, 6min, 6.5min, 7min, 7.5min, 8min, 8.5min, 9min, 9.5min, 10min, etc.).

[0035] Other specific point values ​​within the above numerical range can be selected and will not be described in detail here.

[0036] Preferably, the washing solution comprises EDTA 2-5mM, NaCl 120-140mM, KCl 2.5-3.5mM, MgCl 2 0.5-1.5 mM, NaHCO 3 10-15 mM, Na 2 HPO 4 0.3-0.4 mM, HEPES 5-15 mM and water.

[0037] The concentration of the EDTA can be selected from 2mM, 2.2mM, 2.4mM, 2.6mM, 2.8mM, 3mM, 3.2mM, 3.4mM, 3.6mM, 3.8mM, 4mM, 4.2mM, 4.4mM, 4.6mM, 4.8mM, 5mM, etc., the concentration of NaCl can be selected from 120mM, 122mM, 124mM, 126mM, 128mM, 130mM, 132mM, 134mM, 136mM, 138mM, 140mM, etc., the concentration of KCl can be selected from 2.5mM, 2.6mM, 2.7mM, 2.8mM, 2.9mM, 3mM, 3.1mM, 3.2mM, 3.3mM, 3.4mM, 3.5mM, etc., the concentration of MgCl 2 The concentration of NaHCO can be selected from 0.5mM, 0.6mM, 0.7mM, 0.8mM, 0.9mM, 1mM, 1.1mM, 1.2mM, 1.3mM, 1.4mM, 1.5mM, etc. 3 The concentration can be selected from 10mM, 11mM, 12mM, 13mM, 14mM, 15mM, etc. 2 HPO 4The concentration of can be selected as 0.3mM, 0.31mM, 0.32mM, 0.33mM, 0.34mM, 0.35mM, 0.36mM, 0.37mM, 0.38mM, 0.39mM, 0.4mM, etc., the concentration of HEPES can be selected as 5mM, 6mM, 7mM, 8mM, 9mM, 10mM, 11mM, 12mM, 13mM, 14mM, 15mM, etc., and other specific point values ​​within the above numerical range can be selected, so they will not be described one by one here.

[0038] Preferably, the pH value of the washing liquid is 7-7.4, for example, 7, 7.1, 7.2, 7.3, 7.4, etc. Other specific values ​​within the above numerical range can be selected and will not be described one by one here.

[0039] Preferably, the final platelet concentration in step (4) is 2×10 7 / mL-5×10 7 / mL, for example 2×10 7 / mL, 2.5×10 7 / mL, 3×10 7 / mL, 3.5×10 7 / mL, 4×10 7 / mL, 4.5×10 7 / mL, 5×10 7 Other specific point values ​​within the above numerical range can be selected and will not be described here one by one.

[0040] In a second aspect, the present invention provides a platelet-derived hemostatic agent prepared according to the method for preparing a platelet-derived hemostatic agent according to the first aspect.

[0041] In a third aspect, the present invention provides a use of the platelet-derived hemostatic agent according to the second aspect in preparing tissue or visceral hemostatic materials.

[0042] Compared with the prior art, the present invention has the following beneficial effects:

[0043] 1. hPPL is prepared from platelets and has similar morphological characteristics to normal platelets. It has a high preparation yield and a simple and controllable preparation process.

[0044] 2. hPPL can induce platelet activation and promote platelet aggregation, amplify thrombin generation and fibrin formation, significantly shorten coagulation time, and improve hemostasis efficiency.

[0045] 3. hPPL has platelet surface functional proteins that can adhere to the site of injury, improving coagulation efficiency while reducing the risk of metastasis to the vascular system and distal thrombosis.

[0046] 4. hPPL is a derivative of platelets, does not contain any compound components, does not cause cytotoxicity and inflammatory reactions, has good biosafety, and does not involve issues of material degradation and absorption.

[0047] 5. The composition is clear and easy to modify to suit different application scenarios.

[0048] 6. It has a unique hemostatic mechanism. The PS-mediated thrombin generation and the PTGES / PGE2 / EP3 pathway-mediated platelet activation jointly determine the procoagulant effect of hPPL. The hPPL surface is rich in PS. PS can provide a reaction surface for the formation of the prothrombin complex during the coagulation process, thereby promoting the generation of thrombin, which further mediates platelet activation and fibrin formation. In addition, PTGES is highly expressed on the hPPL surface. PTGES increases the generation of PGE2 in the local plasma at the bleeding site. PGE2 causes platelet activation and aggregation by binding to the EP3 receptor on the platelet surface.

[0049] 7. hPPL has high hemostatic efficiency and can be used for visceral bleeding, especially for hemostatic treatment of visceral bleeding with unknown bleeding points. It has obvious therapeutic advantages compared with commonly used hemostatic materials in clinical practice. In addition, because hPPL has a unique pro-coagulant mechanism, it also has significant advantages in coagulation treatment for patients with coagulation disorders, such as patients taking aspirin for a long time. BRIEF DESCRIPTION OF THE DRAWINGS

[0050] Figure 1 The effect of different calcium ion carrier A23187 treatment concentrations on the procoagulant function of hPPL.

[0051] Figure 2 Figure 1 is the characterization result of hPPL particle size and potential, where Figure A is the hydrated particle size and Figure B is the surface potential.

[0052] Figure 3 Transmission electron microscopy was used to characterize the morphological structure of hPPL.

[0053] Figure 4 These are the results of hPPL protein component identification, where Figure A shows the Coomassie Brilliant Blue staining results of PLT and hPPL whole protein, and Figure B shows the expression identification of hPPL adhesion-related proteins.

[0054] Figure 5 This is the result of identification of hPPL adhesion function.

[0055] Figure 6 The results of hPPL-induced platelet aggregation. Figure A is a representative aggregation curve, and Figure B is the platelet aggregation rate statistics.

[0056] Figure 7These are the test results of hPPL promoting thrombin generation, where Figure A is the thrombin generation curve and Figure B is the maximum thrombin generation.

[0057] Figure 8 hPPL promotes the formation of fibrin network.

[0058] Fig. 9 These are the test results of the relationship between the procoagulant function of hPPL and surface PS, where Figure A is the double-labeling of hPPL and PS by immunofluorescence, Figure B is the aggregation curve of hPPL after treatment with Annexin V, and Figure C is the statistical result of platelet aggregation rate.

[0059] Fig.10 Figure 1 is the expression test result of PTGES, where Figure A is the proteomic difference analysis screening diagram, Figure B is the expression result of PTGES in PLT and hPPL detected by western blot, and Figure C is the statistical result of expression level.

[0060] Fig.11 These are the test results of the effect of MK-886 on platelet aggregation after hPPL treatment, where Figure A is a representative aggregation curve and Figure B is the statistical result of platelet aggregation rate.

[0061] Fig.12 It is the detection result of PGE2 content in plasma after hPPL treatment.

[0062] Fig.13 This is the result of the inhibition of the aggregation-promoting function of hPPL by the EP3 receptor inhibitor, where Figure A is a representative aggregation curve and Figure B is the statistical result of the platelet aggregation rate.

[0063] Fig.14 It is a test of the procoagulant function of hPPL under in vitro conditions.

[0064] Fig.15 hPPL has a significant hemostatic effect in the hemorrhage model induced by liver resection injury, wherein Figure A is a representative picture of the hemostatic process, Figure B is the statistical result of the hemostasis time, and Figure C is the statistical result of the bleeding volume.

[0065] Fig.16 It is the result of the level test of inflammatory factor TNFα.

[0066] Fig.17 hPPL has a significant hemostatic effect in the gastric ulcer bleeding model, where Figure A is a representative picture of the hemostatic process, and Figure B is the statistical result of the hemostatic time.

[0067] Fig.18This is a hPPL stability test, where Figure A shows the particle size of hPPL after different storage time, Figure B shows the potential of hPPL after different storage time, and Figure C shows the platelet aggregation rate induced by hPPL after different storage time.

[0068] Fig.19 These are the Annexin V fluorescence value test results, where Figure A is the Annexin V fluorescence value test result on the platelet surface after A23187 treatment, Figure B is the Annexin V fluorescence value test result on the platelet surface caused by ABT-737 treatment, Figure C is the Annexin V fluorescence value test result on the platelet surface caused by ADP treatment, and Figure D is the Annexin V fluorescence value test result on the platelet surface caused by collagen treatment. DETAILED DESCRIPTION

[0069] The technical solution of the present invention is further described below by specific implementation methods. It should be understood by those skilled in the art that the embodiments are only used to help understand the present invention and should not be regarded as specific limitations of the present invention.

[0070] Anticoagulant: prostaglandin E 15 μM, citric acid 41.6 mM, sodium citrate 85.3 mM, d-glucose 136 mM and water, pH adjusted to 7.4.

[0071] Tyrode's buffer: NaCl 134mM, KCl 2.9mM, MgCl 2 1 mM, NaHCO 3 12 mM, Na 2 HPO 4 0.34 mM, HEPES 10 mM and water, pH adjusted to 7.4.

[0072] Platelet resuspension: prostaglandin E15μM, phenylmethylsulfonyl fluoride 10mM, citric acid 8mM, sodium citrate 17.06mM, d-glucose 27.2mM, NaCl 107.2mM, KCl 2.32mM, MgCl 2 0.8mM, NaHCO 3 9.6 mM, Na 2 HPO 4 0.272 mM, HEPES 8 mM and water, pH adjusted to 7.4.

[0073] Reaction buffer: A23187 20 μM, 2 mM CaCl 2 The solvent was Tyrode's buffer and the pH was adjusted to 7.4.

[0074] Washing solution: EDTA 3mM, the solvent is Tyrode's buffer, and the pH is adjusted to 7.4.

[0075] Example 1

[0076] Preparation of PLT and hPPL

[0077] The preparation method is as follows:

[0078] (1) Mouse whole blood and an anticoagulant were mixed at a volume ratio of 6:1 to obtain anticoagulated whole blood.

[0079] (2) The anticoagulated whole blood was centrifuged at 150 g for 30 min at room temperature to obtain platelet-rich plasma (PRP).

[0080] (3) Transfer the platelet-rich plasma (PRP) into a new tube and centrifuge at 1000 g for 10 min to obtain a platelet precipitate.

[0081] (4) The platelet precipitate was resuspended in a platelet resuspension solution and counted, and then centrifuged at 1000 g for 10 min to obtain platelets (PLT).

[0082] (5) Platelets were collected at 4×10 7 Dissolve in the reaction buffer at a concentration of 100 / mL, mix by inversion 4 times, let stand at 25°C for 5 min, and centrifuge at 5000 g for 8 min at 25°C.

[0083] (6) The product obtained in step (5) was resuspended in washing solution, 4×10 8 The cells were resuspended at a concentration of 1000 g / mL, centrifuged at 25°C and 5000 g for 8 min, washed three times, and resuspended in PBS to obtain (hPPL).

[0084] In order to determine and optimize the preparation process of hPPL, we screened and detected the effects of different concentrations of A23187 on the hemostatic function of hPPL. The concentrations of calcium ion carrier A23187 in the reaction buffer in step (5) were set to 1 μM, 4 μM and 20 μM, respectively, and the other steps remained the same as above.

[0085] The results are as follows Figure 1 As shown, the in vitro blood coagulation experiment detected the coagulation function of hPPL prepared under three conditions. The results showed that hPPL with significant procoagulant function could be prepared only by treatment with 20μM A23187.

[0086] Example 2

[0087] To characterize the characteristics of hPPL, we used dynamic light scattering to detect the hydrated particle size and surface potential of hPPL.

[0088] Test method:

[0089] PLT and hPPL were dissolved in Tyrode's buffer, and the hydrated particle size and zeta potential of PLT and hPPL were detected using a nanoparticle size and zeta potential analyzer (Zetasizer Nano ZS90, Malvern, UK).

[0090] The results are as follows Figure 2 As shown in the figure, it can be seen that hPPL has a particle size and potential similar to normal platelets (PLT).

[0091] Example 3

[0092] Morphology and structure of hPPL and PLT were examined using transmission electron microscopy

[0093] Test method:

[0094] (1) Add 500 μL 2.5% glutaraldehyde (Sigma Aldrich, 1.04239) to the PLT and hPPL precipitates and fix for 4 h.

[0095] (2) The samples were washed three times with sodium acetate buffer and then incubated with 1% osmium tetroxide (Sigma Aldrich, 75633) for 1 h.

[0096] (3) After washing with 0.1 M sodium acetate buffer, the samples were dehydrated with 70%, 80%, 90%, 100%, and 100% ethanol aqueous solutions, respectively.

[0097] (4) After the samples were embedded, they were analyzed using a transmission electron microscope.

[0098] The results are as follows Figure 3 As shown in the figure, hPPL has a similar morphology to PLT, with an intact cell membrane, but the cytoplasmic contents including mitochondria are missing.

[0099] Example 4

[0100] Western blot analysis of the protein composition of hPPL

[0101] Test method:

[0102] (1) Lyse PLT and hPPL using RIPA lysis buffer (Solarbio, R0010) on ice for 30 min, shaking every 5 min.

[0103] (2) Centrifuge the sample at 12000 g for 5 min at 4°C and collect the supernatant.

[0104] (3) The obtained protein lysate was mixed with 5× protein loading buffer (P1040, Solarbio) according to the ratio.

[0105] (4) After mixing, heat in a 100°C water bath for 10 min to denature the protein. After cooling to room temperature, centrifuge at 12,000 g for 5 min and take the supernatant for electrophoresis.

[0106] (5) Protein samples were separated by 10% SDS-PAGE. The gel after electrophoresis was stained in Coomassie Brilliant Blue staining solution (P0017, Beyotime) for 30 min. After decolorization with deionized water for 2 h, the gel was imaged using the Bio-Rad ChemiDox Touch imaging system.

[0107] (6) After completing gel electrophoresis according to the steps in (5), the proteins in the gel were transferred to a polyvinylidene fluoride (PVDF) membrane using a Bio-Rad transfer system, and the transferred membrane was then incubated with 5% skim milk.

[0108] (7) The membrane was incubated with the following primary antibodies: CD41 (Proteintech, 24552-1-AP), GPVI (Abcam, Ab302950), CD42b (ThermoFisher, PA5-86799), GAPDH (Easybio, BE0024-100), and PTGES (Santacruz, sc-365844).

[0109] (8) After incubation with the corresponding secondary antibody, the immunoreactive proteins were detected by enhanced chemiluminescence (ECL) and the blots were displayed on the Bio-Rad ChemiDox Touch imaging system.

[0110] The results are as follows Figure 4 As shown in the figure, hPPL retains the complete PLT proteome and the key adhesion proteins CD41, GPVI and CD42b on the membrane surface.

[0111] Example 5

[0112] Adhesion function test of hPPL

[0113] Test method:

[0114] (1) The concentration of rat type I collagen was adjusted to 2 mg / mL in 0.25% acetic acid.

[0115] (2) Add 500 μL of collagen solution to the confocal dish and incubate at 4°C overnight.

[0116] (3) Before the collagen binding experiment, the confocal dish was incubated with 2% bovine serum albumin and then washed with PBS.

[0117] (4) PLT and hPPL were fluorescently stained using iFluor 488 wheat germ agglutinin (WGA) conjugate membrane dye (I3300, Solarbio).

[0118] (5) 1×10 8 WGA dye-labeled PLTs or hPPLs were added to collagen-coated or uncoated wells.

[0119] (6) After incubation for 2 min, the wells were rinsed with PBS, and then PLTs or hPPLs retained on the bottom of the dish were analyzed using a confocal microscope (Leica SP8 STED 3X).

[0120] The results are as follows Figure 5 As shown in the figure, it can be seen that there is obvious green fluorescence marked with hPPL on the surface of the collagen-coated culture dish, indicating that hPPL still has adhesion function.

[0121] Example 6

[0122] Effect of hPPL on platelet aggregation

[0123] Test method:

[0124] (1) Whole blood of rats was collected and mixed with 3.13% sodium citrate at a volume ratio of 9:1.

[0125] (2) Centrifuge at 180×g for 20 min to obtain PRP.

[0126] (3) Centrifuge part of the PRP at 2000×g for 5 min to obtain platelet poor plasma (PPP).

[0127] (4) Platelet aggregation analysis was performed using an automated light transmission aggregometer (CS-2400, Sysmex, Kobe, Japan) according to the manufacturer's instructions. Specifically, the separated PRP and PPP samples were placed on the sample rack of the CS-2400 analyzer, and the CS-2400 analyzer directly extracted the samples from the tubes. For analysis of hPPL-induced platelet aggregation, the analyzer automatically mixed 140 μL PRP and 20 μL agonist (including hPPL or inhibitor-treated hPPL at a concentration of 3 × 10 8 The instrument automatically monitors the change of light transmittance within 600s, and defines 100% aggregation as the absorbance of 140μL PPP and 20μL saline. The CS-2400 software automatically calculates and displays the aggregation rate.

[0128] The results are as follows Figure 6As shown, hPPL can significantly induce platelet aggregation, while PLT has no significant induction effect on platelet aggregation.

[0129] Example 7

[0130] Effect of hPPL on thrombin generation

[0131] Test method:

[0132] (1) Prepare the reaction solution by dissolving 0.2 mM z-gly-gly-arg-7-amino-4-methylcoumarin (Z-GGR-AMC), 16.6 pmol tissue factor, and 16 mM CaCl2 in Tyrode's buffer.

[0133] (2) Use Tyrode's buffer to adjust the concentration of PLT and hPPL to 2×10 5 Pieces / μL.

[0134] (3) Take 54 μL of the adjusted PLT or hPPL solution and 6 μL of PRP and add them to the wells of a 96-well plate and mix well.

[0135] (4) Add 60 μL of reaction solution into the wells and monitor the fluorescence value changes in the wells in real time at 390 nm excitation wavelength and 460 nm emission wavelength at 37°C using a microplate reader (PE, EnSpire). The higher the fluorescence value, the more thrombin is generated.

[0136] The results are as follows Figure 7 As shown, the addition of hPPL significantly increased the thrombin generation rate in PRP, and the maximum thrombin generation amount also increased significantly.

[0137] Example 8

[0138] Effect of hPPL on fibrin formation

[0139] Test method:

[0140] (1) Whole blood of rats was collected and mixed with 3.13% sodium citrate at a volume ratio of 9:1.

[0141] (2) PRP was obtained by centrifugation at 180 g for 20 min, and PPP was obtained by centrifugation at 2000 g for 5 min. The PRP concentration was then adjusted with PPP to maintain the platelet concentration at 3 × 10 6 Pieces / mL.

[0142] (3) 180 μL PRP, 20 μL CaCl 2 (200 mM) and 20 μL PLT or hPPL (3 × 10 8 / mL) and allowed to stand at room temperature for 30 min to form a fibrin clot.

[0143] (4) The clots were washed with 0.1 M sodium acetate buffer and then fixed in 2.5% glutaraldehyde.

[0144] (5) Wash three times with sodium acetate buffer and incubate with 1% osmium tetroxide for 1 h.

[0145] (6) After washing with 0.1 M sodium acetate buffer, the clots were dehydrated with 70%, 80%, 90%, 100%, and 100% ethanol aqueous solutions, critical point dried with hexamethyldiazane, and finally sputter-coated with gold. The clots were imaged using a scanning electron microscope (Hitachi-SU8220).

[0146] The results are as follows Figure 8 As shown, hPPL treatment significantly enhanced fibrin formation as observed by transmission electron microscopy.

[0147] Example 9

[0148] Procoagulant mechanism of hPPL

[0149] Immunofluorescence staining was used to detect the level of PS on the surface of hPPL.

[0150] Test method:

[0151] (1) PLT and hPPL were washed with phosphate buffered saline (PBS) and then fixed with 4% paraformaldehyde (Biosharp, BL539A) for 10 minutes.

[0152] (2) APC-annexinV (Biolegend, 640920) was stained at 37°C for 30 min to label PS.

[0153] (3) After washing with PBS, PLT and hPPL were stained with WGAAlexa-Fluor 488 dye at 37°C for 20 min. The PLT or hPPL membrane was labeled green by WGA and red by PS. The samples were analyzed using a Leica SP8 STED 3X confocal laser scanning microscope.

[0154] In order to verify that the procoagulant function of hPPL is related to PS, we used Annexin V to block PS on the surface of hPPL and detected the effect of PS blocking on the platelet aggregation-promoting function of hPPL.

[0155] The results are as follows Fig. 9 As shown in the figure, it can be seen that the hPPL surface is rich in PS, and the hPPL-induced platelet aggregation rate decreases after PS blocking, indicating that the PS on the hPPL surface is one of the reasons mediating its procoagulant function.

[0156] PS blockade did not completely block hPPL-induced platelet aggregation, suggesting that other mechanisms are involved in the pro-aggregation function of hPPL.

[0157] The total protein profiles of PLT and hPPL were analyzed using tandem mass tag (TMT) quantitative proteomics technology (Uoji Technology Co., Ltd., Beijing). TM Isobaric Mass Tagging Kit, 90064CH, ThermoFisher Scientific), each group of proteins was stained with TMT reagent, and then the samples were further separated by chromatography and identified by LC-MS / MS (ThermoFisher). The data were analyzed using Proteome Discoverer 2.5 software.

[0158] The results are as follows Fig.10 As shown in the figure, proteomic screening showed that the level of PTGES on the surface of hPPL membrane increased significantly compared with PLT, which may be involved in the aggregation-promoting effect of hPPL. The results of western blot subsequently verified the proteomic results.

[0159] To verify whether PTGES is a key molecule affecting the aggregation-promoting function of hPPL, we treated hPPL with MK-886, a specific inhibitor of PTGES, and then detected the effect of inhibiting PTGES on the aggregation-promoting function of hPPL.

[0160] The results are as follows Fig.11 As shown in the figure, hPPL-induced platelet aggregation was significantly reduced after MK-886 treatment, and the simultaneous treatment of MK-886 and Annexin V resulted in the almost complete shielding of hPPL's ​​pro-aggregation function. Therefore, PTGES is a key molecule for hPPL to exert its pro-coagulant function, and together with PS, it constitutes the pro-coagulant mechanism of hPPL.

[0161] Example 10

[0162] Effect of hPPL on PGE2 Level in PRP

[0163] The effect of hPPL on the level of PGE2 in PRP was detected by enzyme-linked immunosorbent assay.

[0164] Test method:

[0165] (1) Whole blood of rats was collected and mixed with 3.13% sodium citrate at a volume ratio of 9:1.

[0166] (2) Centrifuge at 180 g for 20 min to obtain PRP.

[0167] (3) Take 140 μL PRP and 20 μL PLT solution (3×10 8 / mL), hPPL solution (3×10 8 / mL), hPPL supernatant (hPPL SN) or MK-886-treated hPPL solution were mixed.

[0168] (4) According to the instructions, the PGE2 level of each group was detected using an enzyme-linked immunosorbent assay kit (MEIMIAN, MM-0068R1).

[0169] The results are as follows Fig.12 As shown in the results, co-incubation with hPPL significantly increased the level of PGE2 in plasma, while co-incubation with platelets or hPPL supernatant had no effect on the level of PGE2. In addition, the use of MK-886 to inhibit the function of PTGES inhibited the promotion of hPPL on PGE2 production. The above results indicate that the abundant PTGES on the surface of hPPL can increase the production and content of PGE2 in plasma.

[0170] PGE2 can cause platelet aggregation by binding to EP3 receptors on the platelet surface. To verify whether PTGES in hPPL induces platelet activation through the PGE2 / EP3 pathway, we used L798106, a specific inhibitor of EP3 receptors, to treat platelets in PRP to block the function of EP3 receptors, and then tested whether hPPL could still induce platelet aggregation.

[0171] The results are as follows Fig.13 As shown, hPPL-induced platelet aggregation was significantly decreased after the use of L798106, proving that hPPL induces platelet aggregation through the PTGES / PGE2 / EP3 pathway.

[0172] Embodiment 11

[0173] Procoagulant function of hPPL

[0174] Test method:

[0175] (1) Whole blood of rats was collected and mixed with 3.13% sodium citrate at a volume ratio of 9:1.

[0176] (2) Add CaCl to anticoagulated blood 2 (concentration 20mM) to recalcify it.

[0177] (3) Take 45 μL of recalcified whole blood solution and add 5 μL of PLT or hPPL (3×10 8 / mL).

[0178] (4) The blood of each group was coagulated for 0 min, 1 min, 2 min, 3 min, 4 min, 5 min, 6 min, and 7 min, respectively. At each corresponding time point, 600 μL of deionized water was added to release the unbound blood, and the blood coagulation time and rate were observed.

[0179] The results are as follows Fig.14 As shown, hPPL treatment significantly shortened the coagulation time of whole blood, and treatment of hPPL with MK-886 or Annexin V significantly inhibited the procoagulant function of hPPL.

[0180] Example 12

[0181] Construction of rat liver resection bleeding model

[0182] Traumatic liver hemorrhage remains one of the leading causes of death in humans. At the same time, liver bleeding is usually unavoidable during surgeries such as partial liver resection and liver transplantation. Although a variety of measures are currently taken to control bleeding in the above-mentioned surgeries, efficient and safe hemostasis remains a key issue facing doctors and patients in clinic. Therefore, in order to detect the hemostatic function of hPPL at the in vivo level, we constructed a liver resection bleeding model and used the commonly used hemostatic materials in clinical practice, Xinsuling hemostatic microspheres (MPH) and absorbable hemostatic gauze (FIBRILLAR TM ) as a positive control.

[0183] Test method:

[0184] (1) Select 6-8 week old male SD rats.

[0185] (2) The rats were divided into four groups and anesthetized with 10% chloral hydrate (0.4 mL / 100 g, intraperitoneal injection).

[0186] (3) An incision was made along the midline of the abdomen to expose the first lobe of the right liver of the rat, and a pre-weighed filter paper was placed underneath it.

[0187] (4) Use a scalpel to remove 1 / 3 of the liver to induce liver bleeding.

[0188] (5) Using hPPL (3×10 8 / mL), MPH or FIBRILLAR TM Stop bleeding. The wound surface of the control group was not treated. The bleeding time was recorded, and the total blood loss was calculated by weighing the blood absorbed by the filter paper.

[0189] The results are as follows Fig.15 As shown in the results, hPPL treatment significantly inhibited liver bleeding caused by liver resection, and the bleeding time and amount were significantly shortened compared with the control group. In addition, hPPL has better hemostatic properties than the commonly used hemostatic materials MPH and FIBRILLAR.TM Better hemostasis effect.

[0190] Embodiment 13

[0191] Biosafety

[0192] We detected the level of inflammatory factor TNFα in rat plasma 14 days after rat liver resection and bleeding treatment.

[0193] Test method:

[0194] (1) Whole blood was collected from rats 14 days after recovery from hepatic hemorrhagic injury.

[0195] (2) Centrifuge the whole blood at 3000 g for 15 min and collect the supernatant.

[0196] (3) According to the instructions, an enzyme-linked immunosorbent assay kit (Invitrogen, 88-7340) was used to detect the level of TNFα in each group.

[0197] The results are as follows Fig.16 As shown, MPH treatment significantly increased the level of TNFα in rat plasma, while hPPL showed the best biosafety.

[0198] Embodiment 14

[0199] Peptic ulcer is the main cause of upper gastrointestinal bleeding, with a mortality rate of 5% to 10%. Currently, endoscopic hemostasis is the first-line treatment for peptic ulcer. However, hemostatic treatment of extensive bleeding, especially gastrointestinal bleeding in patients with coagulation disorders, remains a challenge. To further evaluate the hemostatic function of hPPL, we constructed a Forrest class Ib gastric ulcer bleeding model using Panamanian piglets, observed the hemostatic effect and safety of hPPL, and used thrombin, a commonly used hemostatic agent in clinical practice, as a positive control.

[0200] The specific method is as follows:

[0201] (1) Select 25-30kg Bama pigs.

[0202] (2) Due to the strong coagulation function of pigs, it is difficult to induce gastric ulcer bleeding in pigs under endoscopy. Therefore, in order to establish a gastric bleeding model, the anticoagulant aspirin was mixed with food, and each pig was orally administered 2 grams of aspirin per day for five days before surgery.

[0203] (3) The animals were fasted one day before surgery but were allowed to drink water freely.

[0204] (4) On the day of the experiment, 0.5 mg of atropine and 10 mg of dexamethasone were injected intramuscularly, and then the animals were anesthetized with a combination of 0.1-0.2 mg / kg midazolam and 0.25-0.3 mL / kg Sushansan.

[0205] (5) Use a mixed anesthetic drug, prepared from 6 parts of diazepam injection, 6 parts of succinylcholine, and 7 parts of lidocaine to make a 500 mL balanced solution, and slowly drip it intravenously to maintain anesthesia.

[0206] (6) Endoscopic submucosal dissection (ESD) surgery was performed on the pig stomach to establish an ulcer bleeding model. Four ulcer wounds with a diameter of 2-3 cm were constructed in each pig.

[0207] (7) The ulcer wounds were randomly assigned to the following groups: normal saline group, hPPL group and thrombin group.

[0208] (8) After the wound surface bleeds, the drug is applied to the bleeding site through the catheter through the endoscopic biopsy channel every 2 minutes, and the time and amount of the drug used for hemostasis are recorded until hemostasis is completed. The hemostasis or observation endpoint is set at 20 minutes. If the drug is applied 4 times and the bleeding cannot be effectively stopped after 20 minutes of observation, it is considered as hemostasis failure. Heat therapy, clips or other intervention measures are used to stop bleeding to ensure the safety of the animals. The concentrations of hPPL and thrombin are 3×10 8 / mL and 500U / mL.

[0209] The results are as follows Fig.17 As shown, treatment with normal saline or thrombin could not effectively stop bleeding, and after 4 administrations, there was still a lot of bleeding 20 minutes after treatment. However, treatment with hPPL could effectively stop bleeding within 2-4 minutes, showing a significant hemostatic advantage.

[0210] Embodiment 15

[0211] Stability test

[0212] In order to detect the stability of hPPL, we dissolved hPPL in Tyrode's buffer and stored it at 4°C for seven days. The particle size, potential and effect of hPPL on platelet aggregation were detected on day 0, day 2, day 5 and day 7 respectively.

[0213] The results are as follows Fig.18 As shown in the results, hPPL has good stability and can maintain stable particle size, potential and procoagulant function for at least 7 days.

[0214] Example 16

[0215] Based on the important role of PS in the platelet-mediated coagulation process, in order to prepare platelet derivatives with high-efficiency procoagulant function and over-exposed PS, we detected and screened the ability of four inducers to induce platelet PS eversion at different concentrations. Since both platelet activators and platelet apoptosis inducers can induce platelet PS eversion, we selected two activators ADP and collagen, one apoptosis inducer ABT-737, and one inducer A23187 that can induce activation and apoptosis at the same time to stimulate platelets at different concentrations, and then used flow cytometry to detect the PS eversion after different treatments.

[0216] The test method is as follows:

[0217] (1) Platelets are obtained according to the above method.

[0218] (2) Different concentrations of collagen, ADP, ABT-737 or A23187 were dissolved in Tyrode's buffer to obtain reaction buffer. A23187 required the addition of 2 mM CaCl 2 .

[0219] (3) Platelets were divided into 2×10 7 Dissolve in the reaction buffer at a concentration of 100 / mL, mix by inversion 4 times, let stand at 25°C for 5 min, and centrifuge at 5000 g for 8 min at 25°C.

[0220] (4) The product obtained in step (3) was resuspended in washing solution, 2×10 8 The cells were resuspended at a concentration of 1000 g / mL, centrifuged at 25°C and 5000 g for 8 min, washed three times, and resuspended in PBS.

[0221] (5) The obtained product was stained with APC-annexin V (Biolegend, 640920) at 37°C for 15 min to label PS, and the exposure level of PS on the surface of each group of platelet derivatives was detected by flow cytometry.

[0222] The results are as follows Fig.19 As shown, A23187 can effectively induce platelet PS eversion. Compared with normal platelets, the PS signal on the surface of platelet derivatives treated with A23187 can increase by 75 times and is concentration-dependent. Its induction ability is much greater than that of other reagents.

[0223] The hemostatic agent hPPL prepared by the present invention can be widely used in the hemostatic treatment of tissue or organ bleeding caused by trauma, surgery, military environment, disease, etc. Since hPPL has the function of adhering to damaged blood vessels, it has significant advantages in the treatment of chronic bleeding with unknown bleeding points, such as gastrointestinal bleeding; in addition, since hPPL has a unique procoagulant mechanism, it also has significant advantages in the coagulation treatment of patients with coagulation disorders, such as patients taking aspirin for a long time.

[0224] The preparation process of the present invention is simple and controllable, eliminates the toxic effects and degradation problems of the compounds and other materials themselves, and the product has high procoagulant efficiency. Compared with existing hemostatic materials, the platelet-derived hemostatic agent has good biocompatibility, does not require absorption and degradation, has a unique procoagulant mechanism, has a more significant hemostatic effect, and has a wider range of applications.

[0225] The applicant declares that the present invention uses the above-mentioned embodiments to illustrate the preparation method of a platelet-derived hemostatic agent of the present invention, its product and application, but the present invention is not limited to the above-mentioned embodiments, that is, it does not mean that the present invention must rely on the above-mentioned embodiments to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.

[0226] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, a variety of simple modifications can be made to the technical solution of the present invention, and these simple modifications all belong to the protection scope of the present invention.

[0227] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.

Claims

1. A method for preparing a platelet-derived hemostatic agent, characterized in that: The preparation method comprises: (1) Mixing whole blood with an anticoagulant and centrifuging to obtain platelet-rich plasma; (2) centrifuging the platelet-rich plasma to obtain a platelet precipitate; (3) resuspending the platelet precipitate using a platelet resuspension solution, and centrifuging to obtain platelets; (4) The platelets are mixed with a buffer solution containing a calcium ion carrier, allowed to stand, and then centrifuged to obtain the product.

2. The method for preparing the platelet-derived hemostatic agent according to claim 1, characterized in that: The whole blood includes mouse whole blood, pig whole blood or human whole blood.

3. The method for preparing the platelet-derived hemostatic agent according to claim 1 or 2, characterized in that: The volume ratio of whole blood to anticoagulant is (5-7):1; Preferably, the anticoagulant comprises prostaglandin E12-10 μM, citric acid 35-45 mM, sodium citrate 75-90 mM, d-glucose 120-140 mM and water; Preferably, the pH of the anticoagulant is 7-7.

4.

4. The method for preparing a platelet-derived hemostatic agent according to any one of claims 1 to 3, characterized in that: The centrifugation speed in step (1) is 100-180g and the time is 20-40min; Preferably, the centrifugal speed in step (2) and step (3) is independently 1000-2000 g, and the time is independently 5-15 min.

5. The method for preparing a platelet-derived hemostatic agent according to any one of claims 1 to 4, characterized in that: The platelet resuspension solution comprises prostaglandin E12-10 μM, citric acid 7-8 mM, sodium citrate 15-18 mM, d-glucose 24-28 mM, NaCl 96-112 mM, KCl 2-2.8 mM, MgCl2 0.5-1.2 mM, NaHCO3 8-12 mM, Na2HPO4 0.24-0.32 mM, HEPES 4-12 mM, phenylmethylsulfonyl fluoride 6-10 mM and water; Preferably, the pH of the platelet resuspension is 7-7.

4.

6. The method for preparing a platelet-derived hemostatic agent according to any one of claims 1 to 5, characterized in that: The buffer containing calcium ionophore includes calcium ionophore 15-30 μM, CaCl2 1-2 mM, NaCl 120-140 mM, KCl 2.5-3.5 mM, MgCl2 0.5-1.5 mM, NaHCO3 10-15 mM, Na2HPO4 0.3-0.4 mM, HEPES 5-15 mM and water; Preferably, the pH of the buffer solution containing calcium ion carrier is 7-7.4; Preferably, the calcium ion carrier comprises A23187; Preferably, the standing temperature in step (4) is 20-25° C. and the standing time is 3-8 min.

7. The method for preparing a platelet-derived hemostatic agent according to any one of claims 1 to 6, characterized in that: Step (4) further comprises washing 1-3 times after the centrifugation; Preferably, the washing method specifically comprises: resuspending the product obtained by centrifugation with a washing solution, and centrifuging at 4500-6000 g for 5-10 min; Preferably, the washing solution comprises EDTA 2-5 mM, NaCl 120-140 mM, KCl 2.5-3.5 mM, MgCl2 0.5-1.5 mM, NaHCO3 10-15 mM, Na2HPO4 0.3-0.4 mM, HEPES 5-15 mM and water; Preferably, the pH of the washing liquid is 7-7.

4.

8. The method for preparing a platelet-derived hemostatic agent according to any one of claims 1 to 7, characterized in that: The final platelet concentration in step (4) is 2×10 7 / mL-5×10 7 Pieces / mL.

9. A platelet-derived hemostatic agent prepared by the method for preparing a platelet-derived hemostatic agent according to any one of claims 1 to 8.

10. Use of the platelet-derived hemostatic agent according to claim 9 in preparing tissue or visceral hemostatic materials.